Acea Therapeutics, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
Phase 1
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: AC0058TADrug: Placebo AC0058TA
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- ACEA Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03878303
- Locations
- ๐บ๐ธ
Metroplex Clinical Research Center, Dallas, Texas, United States
Study of AC0058TA in Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AC0058TADrug: Placebo capsules
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- ACEA Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT02847325
- Locations
- ๐บ๐ธ
Covance Clinical Development Services, Dallas, Texas, United States
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- ACEA Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02448251
- Locations
- ๐บ๐ธ
Stanford University, Palo Alto, California, United States
๐บ๐ธCity of Hope Comprehensive Cancer Center, Duarte, California, United States
๐บ๐ธEmory University School of Medicine, Atlanta, Georgia, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath